Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
You take care of your investments. We like that.
Upgrade to Premium to access your Watchlist and more.
Invesco Biotechnology & Genome ETF
ETF
PBE
Payout Change
Pending
Price as of:
$69.5587
+1.0
+1.46%
primary theme
Health Care Sector Equity
PBE (ETF)
Invesco Biotechnology & Genome ETF
Payout Change
Pending
Price as of:
$69.5587
+1.0
+1.46%
primary theme
Health Care Sector Equity
PBE (ETF)
Invesco Biotechnology & Genome ETF
Payout Change
Pending
Price as of:
$69.5587
+1.0
+1.46%
primary theme
Health Care Sector Equity
Name
As of 11/22/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
5.7%
1 yr return
22.7%
3 Yr Avg Return
-1.0%
5 Yr Avg Return
5.5%
Net Assets
$246 M
Holdings in Top 10
60.6%
52 WEEK LOW AND HIGH
$68.6
$56.50
$72.24
Expenses
OPERATING FEES
Expense Ratio 0.58%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 151.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Exchange Traded Fund
Name
As of 11/22/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
PBE - Profile
Distributions
- YTD Total Return 5.7%
- 3 Yr Annualized Total Return -1.0%
- 5 Yr Annualized Total Return 5.5%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.30%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Quarterly
Fund Details
-
Legal NameInvesco Biotechnology & Genome ETF
-
Fund Family NameINVESCOETF
-
Inception DateJun 23, 2005
-
Shares Outstanding3820000
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerPeter Hubbard
Fund Description
The Fund generally will invest at least 90% of its total assets in securities that comprise the Underlying Index.
Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC (“ICE Data” or the “Index Provider”) compiles and maintains the Underlying Index, which is composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, and are companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. These companies may include biopharmaceutical companies that actively participate in the research and development, animal testing and partial human testing phases of drug development, typically using biotechnological techniques that require the use of living organisms, cells and/or components of cells; outsourced services companies that utilize drug delivery technologies in the development of therapeutics for the biopharmaceutical industry or provide biopharmaceutical companies with novel biological targets and drug leads, and scientific products such as bio-analytical instruments, reagents, and chemicals.
As of June 30, 2024, the Underlying Index was comprised of 30 constituents with market capitalizations ranging from $653.6 million to $167.6 billion.
The Fund employs a “full replication” methodology in seeking to track the Underlying Index, meaning that the Fund generally invests in all of the securities comprising the Underlying Index in proportion to their weightings in the Underlying Index.
The Fund is “non-diversified” and therefore is not required to meet certain diversification requirements under the Investment Company Act of 1940, as amended (the “1940 Act”).
Concentration Policy. The Fund will concentrate its investments (i.e., invest 25% or more of the value of its total assets) in securities of issuers in any one industry or group of industries only to the extent that the Underlying Index reflects a concentration in that industry or group of industries. The Fund will not otherwise concentrate its investments in securities of issuers in any one industry or group of industries. As of April 30, 2024, the Fund had significant exposure to the biotechnology and genome industry. The Fund’s portfolio holdings, and the extent to which it concentrates its investments, are likely to change over time.
PBE - Performance
Return Ranking - Trailing
| Period | PBE Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 5.7% | -27.4% | 20.8% | 67.30% |
| 1 Yr | 22.7% | -14.9% | 52.4% | 19.50% |
| 3 Yr | -1.0%* | -28.3% | 10.0% | 73.03% |
| 5 Yr | 5.5%* | -7.8% | 12.3% | 75.34% |
| 10 Yr | 3.6%* | 0.3% | 13.0% | 90.99% |
* Annualized
Return Ranking - Calendar
| Period | PBE Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 3.7% | -12.6% | 19.0% | 38.36% |
| 2022 | -10.8% | -53.9% | 3.2% | 30.26% |
| 2021 | 1.5% | -39.6% | 24.2% | 42.11% |
| 2020 | 25.6% | -13.6% | 178.2% | 16.78% |
| 2019 | 18.7% | 3.8% | 63.8% | 69.92% |
Total Return Ranking - Trailing
| Period | PBE Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 5.7% | -27.4% | 20.8% | 67.30% |
| 1 Yr | 22.7% | -14.9% | 52.4% | 19.50% |
| 3 Yr | -1.0%* | -28.3% | 10.0% | 73.03% |
| 5 Yr | 5.5%* | -7.8% | 12.3% | 75.34% |
| 10 Yr | 3.6%* | 0.3% | 13.0% | 90.99% |
* Annualized
Total Return Ranking - Calendar
| Period | PBE Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 3.7% | -12.6% | 19.0% | 59.12% |
| 2022 | -10.8% | -53.9% | 3.7% | 43.42% |
| 2021 | 1.5% | -33.9% | 26.0% | 77.63% |
| 2020 | 25.7% | -0.7% | 180.6% | 38.26% |
| 2019 | 18.7% | 4.6% | 63.8% | 91.73% |
PBE - Holdings
Concentration Analysis
| PBE | Category Low | Category High | PBE % Rank | |
|---|---|---|---|---|
| Net Assets | 246 M | 6.66 M | 45.7 B | 63.52% |
| Number of Holdings | 33 | 25 | 430 | 94.34% |
| Net Assets in Top 10 | 164 M | 2.12 M | 22.1 B | 59.75% |
| Weighting of Top 10 | 60.58% | 18.4% | 79.7% | 14.47% |
Top 10 Holdings
- Invesco Private Prime Fund 14.46%
- Invesco Private Government Fund 5.54%
- Illumina, Inc. 5.41%
- Gilead Sciences, Inc. 5.37%
- Incyte Corp. 5.13%
- BioMarin Pharmaceutical Inc. 5.11%
- Vertex Pharmaceuticals Inc. 5.01%
- Regeneron Pharmaceuticals, Inc. 5.00%
- Amgen Inc. 5.00%
- Neurocrine Biosciences, Inc. 4.55%
Asset Allocation
| Weighting | Return Low | Return High | PBE % Rank | |
|---|---|---|---|---|
| Stocks | 100.04% | 87.34% | 106.13% | 2.52% |
| Cash | 20.06% | 0.00% | 33.01% | 2.52% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 49.06% |
| Other | 0.00% | -22.99% | 23.24% | 53.46% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 30.52% |
| Bonds | 0.00% | 0.00% | 12.39% | 47.80% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | PBE % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 17.53% |
| Utilities | 0.00% | 0.00% | 0.00% | 26.62% |
| Technology | 0.00% | 0.00% | 22.69% | 33.12% |
| Real Estate | 0.00% | 0.00% | 5.89% | 30.52% |
| Industrials | 0.00% | 0.00% | 7.02% | 31.82% |
| Financial Services | 0.00% | 0.00% | 1.60% | 49.35% |
| Energy | 0.00% | 0.00% | 0.00% | 26.62% |
| Communication Services | 0.00% | 0.00% | 9.11% | 29.87% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 35.06% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 31.82% |
| Basic Materials | 0.00% | 0.00% | 7.16% | 52.60% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | PBE % Rank | |
|---|---|---|---|---|
| US | 100.04% | 66.06% | 104.41% | 1.89% |
| Non US | 0.00% | 0.00% | 28.87% | 75.47% |
PBE - Expenses
Operational Fees
| PBE Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.58% | 0.08% | 4.48% | 83.02% |
| Management Fee | 0.50% | 0.03% | 1.25% | 13.84% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| PBE Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| PBE Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| PBE Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 151.00% | 0.00% | 238.00% | 94.81% |
PBE - Distributions
Dividend Yield Analysis
| PBE | Category Low | Category High | PBE % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 6.24% | 35.22% |
Dividend Distribution Analysis
| PBE | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Quarterly | Annual | Quarterly | Annual |
Net Income Ratio Analysis
| PBE | Category Low | Category High | PBE % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.30% | -2.54% | 1.85% | 54.61% |
Capital Gain Distribution Analysis
| PBE | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Jun 24, 2024 | $0.008 | OrdinaryDividend |
| Mar 18, 2024 | $0.024 | OrdinaryDividend |
| Jun 20, 2023 | $0.014 | OrdinaryDividend |
| Mar 23, 2020 | $0.029 | OrdinaryDividend |
| Sep 24, 2018 | $0.002 | OrdinaryDividend |
| Jun 16, 2017 | $0.215 | OrdinaryDividend |
| Mar 17, 2017 | $0.056 | OrdinaryDividend |
| Dec 16, 2016 | $0.121 | OrdinaryDividend |
| Sep 16, 2016 | $0.028 | OrdinaryDividend |
| Dec 18, 2015 | $0.308 | OrdinaryDividend |
| Sep 18, 2015 | $0.137 | OrdinaryDividend |
| Jun 19, 2015 | $0.123 | OrdinaryDividend |
| Sep 19, 2014 | $0.043 | OrdinaryDividend |
| Jun 20, 2014 | $0.234 | OrdinaryDividend |
| Dec 18, 2009 | $0.076 | OrdinaryDividend |
PBE - Fund Manager Analysis
Managers
Peter Hubbard
Start Date
Tenure
Tenure Rank
Jun 01, 2007
15.01
15.0%
Peter Hubbard, Vice President and Director of Portfolio Management of the Invesco PowerShares Capital Management LLC. Mr. Hubbard has been a Portfolio Manager of the Adviser since June 2007 and has been associated with the Adviser since 2005. Prior to joining the Invesco PowerShares Capital Management LLC, Hubbard was a research analyst and trader for Ritchie Capital from September 2003 to May 2005.
Michael Jeanette
Start Date
Tenure
Tenure Rank
Aug 30, 2008
13.76
13.8%
Michael Jeanette, Senior Portfolio Manager of Invesco Capital Management LLC, has been associated with Invesco Capital Management LLC since 2008. Prior to joining Invesco Capital Management LLC, Mr. Jeanette was a trust advisor and GM of Chicago based Richard Lamb, LLC from 1998 to 2007.
Tony Seisser
Start Date
Tenure
Tenure Rank
Aug 29, 2014
7.76
7.8%
Tony Seisser is a Vice President and Portfolio Manager of Invesco PowerShares Capital Management LLC since December 2013. Prior to joining the Adviser, he was employed by Guggenheim Funds Distributors, Inc. where he was a trader from 2010 to 2013. Prior to that, Mr. Seisser was a compliance investigator at the Chicago Board of Options Exchange and Chicago Futures Exchange from 2008 to 2010.
Pratik Doshi
Start Date
Tenure
Tenure Rank
Aug 28, 2020
1.76
1.8%
Pratik Doshi is a Portfolio Manager of Invesco Capital Management. Mr. Doshi has been a Portfolio Manager of Invesco Capital Management since October 2019 and has been associated with Invesco Capital Management since 2018. Prior to joining Invesco Capital Management, Mr. Doshi was a business student in the MBA program at the University of Chicago from 2016 to 2018. From 2014 to 2016, he served as a Vice President at Bank of America, and from 2007 to 2014 he served as Assistant Vice President at Barclays Capital.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.88 | 0.25 |
